Eli Lilly and Co.

Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19

Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19

INDIANAPOLIS — Eli Lilly and Co. and the UnitedHealth Group have announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals. Bamlanivimab recently received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration for the treatment of mild to moderate COVID-19 patients who are at high risk

Lilly and Ypsomed collaborate to advance an automated insulin delivery system

Lilly and Ypsomed collaborate to advance an automated insulin delivery system

INDIANAPOLIS — Eli Lilly and Co. and Ypsomed announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly’s connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.

Eli Lilly’s bamlanivimab gets EUA from FDA to treat COVID-19

Eli Lilly’s bamlanivimab gets EUA from FDA to treat COVID-19

INDIANAPOLIS — The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Co. investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high

U.S. signs $375 million deal for Lilly COVID-19 antibody drug

U.S. signs $375 million deal for Lilly COVID-19 antibody drug

INDIANAPOLIS — Eli Lilly and Co. announced  an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The U.S. government will accept the vials of bamlanivimab if it is granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration

Lilly reports new data indicating rise in opioid use for migraine treatment

Lilly reports new data indicating rise in opioid use for migraine treatment

INDIANAPOLIS — Eli Lilly and Co. announced the upcoming presentation of data indicating rising rates of opioid use for the treatment of migraine based on results from the OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) study. These findings will be presented on Saturday, July 13, 2019, at the 61st Annual Scientific Meeting

Lilly helping people prepare for disasters, making meds available

Lilly helping people prepare for disasters, making meds available

INDIANAPOLIS —  The 2019 Atlantic hurricane season begins June 1. With natural disasters and extreme weather on the rise, it’s critical to be prepared and ready to respond. That’s why Eli Lilly and Co. and two leading disaster relief organizations – Healthcare Ready and Direct Relief – are working to help people prepare for disasters and

Lilly to introduce lower-priced insulin

Lilly to introduce lower-priced insulin

INDIANAPOLIS — Reinforcing their commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Co. announced it will introduce a lower-priced version of Humalog (insulin lispro injection 100 units/mL) in the United States — providing people with diabetes an insulin option that will have a list price 50 percent lower than the current

Lilly to acquire Loxo Oncology

Lilly to acquire Loxo Oncology

INDIANAPOLIS — Eli Lilly and Co. and Loxo Oncology, Inc. today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be the largest and latest in a

Lilly’s Emgality gets FDA approval for the preventive treatment of migraine in adults

Lilly’s Emgality gets FDA approval for the preventive treatment of migraine in adults

INDIANAPOLIS — Eli Lilly and Co. announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Emgality will be available to patients